Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients

Abstract Background Efficient monitoring and control of coronavirus disease 2019 (COVID-19) require access to diagnostic tests, serological testing is desirable. In the current study, antibodies were investigated in patients recently diagnosed with severe acute respiratory syndrome 2 (SARS-CoV-2) infection. Methods Cross-sectional data obtained from 245 whom SARS-CoV-2 infection had been confirmed via real-time reverse transcriptase-polymerase chain reaction between March October 2020. Serum samples acquired 60 days following onset COVID-19 symptoms or first detection asymptomatic patients. All specimens tested simultaneously using an IgM/IgG rapid test (RDT), IgG nucleocapsid protein-based chemiluminescent microparticle immunoassay (CMIA), IgG, IgA spike enzyme-linked immunosorbent assays (ELISAs). Blood donor 2018 used as negative controls. Results The sensitivity specificity RDT compared immunoassays standards. exhibited 97.5% 89.4% a CMIA 98.4% sensitivity, 78.8% ELISA IgG. IgM, seropositivity rates low 1 weeks after symptom RNA. IgM rate began decreasing 4 weeks, whereas remained at appreciable levels over 8-week study period. No cross-reactivity seasonal coronaviruses was detected. Conclusions alone combined molecular tests may be useful for identifying recent